001     834832
005     20240625095121.0
024 7 _ |a 10.1021/acs.jmedchem.7b00472
|2 doi
024 7 _ |a 0022-2623
|2 ISSN
024 7 _ |a 0095-9065
|2 ISSN
024 7 _ |a 1520-4804
|2 ISSN
024 7 _ |a 1943-2992
|2 ISSN
024 7 _ |a 2128/14926
|2 Handle
024 7 _ |a WOS:000405764900035
|2 WOS
024 7 _ |a altmetric:21031446
|2 altmetric
024 7 _ |a pmid:28603987
|2 pmid
037 _ _ |a FZJ-2017-04723
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Ortega, Jose Antonio
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells
260 _ _ |a Washington, DC
|c 2017
|b ACS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1515071174_1060
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metabolism and signaling of sphingolipids. A growing body of evidence links deregulation of sphingolipids to several diseases, including cancer. Indeed, AC expression is abnormally high in melanoma cells. AC inhibition may thus be key to treating malignant melanoma. Here, we have used a systematic scaffold exploration to design a general pharmacophore for AC inhibition. This pharmacophore comprises a 6 + 5 fused ring heterocycle linked to an aliphatic substituent via a urea moiety. We have thus identified the novel benzimidazole derivatives 10, 21, 27, and 30, which are highly potent AC inhibitors. Their chemical and metabolic stabilities are comparable or superior to those of previously reported AC inhibitors. Moreover, they are potent against endogenous AC in intact melanoma cells. These novel inhibitors merit further characterization and can serve as a promising starting point for the discovery of new antimelanoma therapeutics.
536 _ _ |a 899 - ohne Topic (POF3-899)
|0 G:(DE-HGF)POF3-899
|c POF3-899
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Arencibia, Jose M.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a La Sala, Giuseppina
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Borgogno, Marco
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Bauer, Inga
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Bono, Luca
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Braccia, Clarissa
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Armirotti, Andrea
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Girotto, Stefania
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Ganesan, Anand
|0 P:(DE-HGF)0
|b 9
700 1 _ |a De Vivo, Marco
|0 P:(DE-Juel1)167585
|b 10
|e Corresponding author
773 _ _ |a 10.1021/acs.jmedchem.7b00472
|g Vol. 60, no. 13, p. 5800 - 5815
|0 PERI:(DE-600)1491411-6
|n 13
|p 5800 - 5815
|t Journal of medicinal chemistry
|v 60
|y 2017
|x 1520-4804
856 4 _ |u https://juser.fz-juelich.de/record/834832/files/acs.jmedchem.7b00472.pdf
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/834832/files/acs.jmedchem.7b00472.gif?subformat=icon
|x icon
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/834832/files/acs.jmedchem.7b00472.jpg?subformat=icon-1440
|x icon-1440
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/834832/files/acs.jmedchem.7b00472.jpg?subformat=icon-180
|x icon-180
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/834832/files/acs.jmedchem.7b00472.jpg?subformat=icon-640
|x icon-640
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/834832/files/acs.jmedchem.7b00472.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:834832
|p openaire
|p open_access
|p driver
|p VDB
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 10
|6 P:(DE-Juel1)167585
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF3-890
|0 G:(DE-HGF)POF3-899
|2 G:(DE-HGF)POF3-800
|v ohne Topic
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J MED CHEM : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J MED CHEM : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)IAS-5-20120330
|k IAS-5
|l Computational Biomedicine
|x 0
920 1 _ |0 I:(DE-Juel1)INM-9-20140121
|k INM-9
|l Computational Biomedicine
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)IAS-5-20120330
980 _ _ |a I:(DE-Juel1)INM-9-20140121
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21